More about

Car T-Cell Therapy

News
February 14, 2023
2 min read
Save

CAR T-cell recipients receive more psychological support, fear cancer progression less

CAR T-cell recipients receive more psychological support, fear cancer progression less

Patients who received chimeric antigen receptor T cells for relapsed or refractory diffuse large B-cell lymphoma feared disease progression less than those who received standard regimens, results of a cross-sectional study showed.

News
February 06, 2023
5 min read
Save

CAR-T delays necessitate ongoing coordination of bridging therapy for multiple myeloma

CAR-T delays necessitate ongoing coordination of bridging therapy for multiple myeloma

Chimeric antigen receptor T cells are one of the newest immunotherapy options for multiple myeloma treatment.

News
February 02, 2023
44 min listen
Save

Restoring Trust in the Health Care System with Christopher Heery, MD

Restoring Trust in the Health Care System with Christopher Heery, MD

In this episode, host Shikha Jain, MD, speaks with Christopher Heery, MD, of Arcellx, Inc. about making the transition from physician to chief medical officer, providing more access and education for clinical trials and more.

News
January 31, 2023
2 min read
Save

BLOG: Creating systemic change with the ASTCT-NMDP ACCESS Initiative

BLOG: Creating systemic change with the ASTCT-NMDP ACCESS Initiative

“With great power comes great responsibility.”

News
January 27, 2023
1 min read
Save

Carvykti regimen extends PFS in advanced multiple myeloma

Carvykti regimen extends PFS in advanced multiple myeloma

A phase 3 trial of ciltacabtagene autoleucel for adults with relapsed or refractory multiple myeloma met its primary endpoint, according to the agent’s manufacturer.

News
January 26, 2023
1 min read
Save

Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup

Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup

A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.

News
January 13, 2023
2 min read
Save

Blood test predicts CAR-T response in non-Hodgkin lymphoma

Blood test predicts CAR-T response in non-Hodgkin lymphoma

A risk model based on low-pass whole-genome sequencing of cell-free DNA predicted which patients are more likely to respond to chimeric antigen receptor T-cell therapy for large B-cell lymphoma, study results showed.

News
January 12, 2023
2 min watch
Save

Efficacy, safety data support use of lisocabtagene maraleucel at community sites

Efficacy, safety data support use of lisocabtagene maraleucel at community sites

NEW ORLEANS — Lisocabtagene maraleucel can be administered safely in the community setting to patients relapsed or refractory large B-cell lymphoma, according to phase 2 study results.

News
January 12, 2023
3 min watch
Save

VIDEO: Impact of CAR T-cell therapy on DLBCL care

VIDEO: Impact of CAR T-cell therapy on DLBCL care

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

News
January 12, 2023
2 min watch
Save

VIDEO: Challenges in managing patients with DLBCL

VIDEO: Challenges in managing patients with DLBCL

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

View more